| Literature DB >> 33437789 |
Jialyu Huang1, Jiaying Lin1, Renfei Cai1, Xuefeng Lu1, Ning Song2, Hongyuan Gao1, Yanping Kuang1.
Abstract
BACKGROUND: Peak endometrial thickness (EMT), measured on the end of follicular phase or early luteal phase, is the most widely used marker for endometrial receptivity during infertility treatment. However, the clinical significance of follicular-to-luteal EMT change remains unclear. We aimed to study whether the change of EMT between the day of human chorionic gonadotrophin (hCG) triggering and the day of frozen-thawed embryo transfer (FET) has any influence on pregnancy outcomes in modified natural cycles (mNCs).Entities:
Keywords: Endometrial thickness (EMT); frozen-thawed embryo transfer (FET); modified natural cycle (NC); pregnancy
Year: 2020 PMID: 33437789 PMCID: PMC7791260 DOI: 10.21037/atm-20-1459
Source DB: PubMed Journal: Ann Transl Med ISSN: 2305-5839
Baseline characteristics stratified by the percent change of endometrial thickness.
| Characteristics | >5% decrease (n=405) | ±5% plateau (n=1,259) | >5% increase (n=1,104) | P value |
|---|---|---|---|---|
| Maternal age (years) | 32.2±4.7 | 32.1±4.7 | 32.0±4.4 | 0.608 |
| Maternal BMI (kg/m2) | 21.51±2.62 | 21.20±2.70 | 21.22±2.63 | 0.057 |
| Nulligravida, n (%) | 217 (53.6) | 652 (51.8) | 623 (56.4) | 0.077 |
| Nulliparity, n (%) | 365 (90.1) | 1142 (90.7) | 1009 (91.4) | 0.712 |
| Duration of infertility (years) | 3.9±3.2 | 4.2±3.3 | 3.9±3.0 | 0.073 |
| Infertility diagnosis, n (%) | 0.700 | |||
| Male factor | 53 (13.1) | 192 (15.3) | 154 (13.9) | |
| Tubal factor | 218 (53.8) | 655 (52.0) | 585 (53.0) | |
| Other | 15 (3.7) | 53 (4.2) | 54 (4.9) | |
| Unexplained | 29 (7.2) | 83 (6.6) | 89 (8.1) | |
| Combined | 90 (22.2) | 276 (21.9) | 222 (20.1) | |
| Ovarian stimulation protocol, n (%) | <0.001 | |||
| GnRH antagonist | 9 (2.2) | 17 (1.4) | 25 (2.3) | |
| GnRH agonist short | 70 (17.3) | 266 (21.1) | 185 (16.8) | |
| Mild stimulation | 140 (34.6) | 677 (53.8) | 421 (38.1) | |
| Progestin-primed ovarian stimulation | 186 (45.9) | 299 (23.7) | 473 (42.8) | |
| Fertilization method, n (%) | 0.207 | |||
| IVF | 265 (65.4) | 795 (63.1) | 693 (62.8) | |
| ICSI | 99 (24.4) | 340 (27.0) | 273 (24.7) | |
| IVF + ICSI | 41 (10.1) | 124 (9.8) | 138 (12.5) | |
| Year of treatment, n (%) | <0.001 | |||
| Before 2013 | 128 (31.6) | 617 (49.0) | 393 (35.6) | |
| After 2013 | 277 (68.4) | 642 (51.0) | 711 (64.4) |
Values are presented as mean ± standard deviation or number (percentage). BMI, body mass index; GnRH, gonadotropin-releasing hormone; IVF, in vitro fertilization; ICSI, intracytoplasmic sperm injection.
Cycle characteristics and pregnancy outcomes stratified by the percent change of endometrial thickness
| Characteristics | >5% decrease (n=405) | ±5% plateau (n=1,259) | >5% increase (n=1,104) | P value |
|---|---|---|---|---|
| Cycle characteristics | ||||
| Duration of follicular growth (days) | 13.2±2.1 | 13.4±3.8 | 13.3±2.2 | 0.498 |
| No. of >14 mm follicles on trigger day | 1.0±0.2 | 1.0±0.1 | 1.0±0.1 | 0.362 |
| Peak estradiol level (pg/mL) | 260.1±96.3 | 256.8±87.6 | 254.7±87.3 | 0.569 |
| EMT on trigger day (mm) | 11.25±2.06 | 11.37±2.34 | 10.04±1.66 | <0.001 |
| EMT on FET day (mm) | 9.70±1.87 | 11.38±2.35 | 12.21±2.06 | <0.001 |
| Post-trigger EMT absolute difference (mm) | −1.55±0.91 | 0.01±0.17 | 2.17±1.15 | <0.001 |
| Post-trigger EMT percent difference (%) | −13.6±7.1 | 0.1±1.6 | 22.1±12.2 | <0.001 |
| Spontaneous LH surge, n (%) | 255 (63.0) | 791 (62.8) | 616 (55.8) | 0.001 |
| No. of embryos transferred, n (%) | 0.100 | |||
| Single | 51 (12.6) | 142 (11.3) | 157 (14.2) | |
| Double | 354 (87.4) | 1,117 (88.7) | 947 (85.8) | |
| Embryo stage at transfer, n (%) | 0.264 | |||
| Cleavage stage | 359 (88.6) | 1,146 (91.0) | 1,008 (91.3) | |
| Blastocyst stage | 46 (11.4) | 113 (9.0) | 96 (8.7) | |
| Transfer of ≥1 top-quality embryo, n (%) | 93 (23.0) | 338 (26.8) | 255 (23.1) | 0.071 |
| Pregnancy outcomes | ||||
| Positive hCG test, n (%) | 209 (51.6) | 701 (55.7) | 597 (54.1) | 0.341 |
| Clinical pregnancy, n (%) | 194 (47.9) | 652 (51.8) | 554 (50.2) | 0.374 |
| Intrauterine implantation, n/N (%) | 246/759 (32.4) | 848/2,376 (35.7) | 713/2,051 (33.9) | 0.197 |
| Early miscarriage, n/N (%) | 25/194 (12.9) | 98/652 (15.0) | 76/554 (13.7) | 0.688 |
| Ongoing pregnancy, n (%) | 165 (40.7) | 543 (43.1) | 474 (42.9) | 0.686 |
| Live birth, n (%) | 161 (39.8) | 528 (41.9) | 468 (42.4) | 0.649 |
Values are presented as mean ± standard deviation or number (percentage). EMT, endometrial thickness; FET, frozen-thawed embryo transfer; LH, luteinizing hormone; hCG, human chorionic gonadotrophin.
Figure 1Crude and adjusted odds ratios of pregnancy outcomes for (A) EMT >5% decrease and (B) EMT >5% increase in comparison with the EMT plateau (±5%) group. EMT, endometrial thickness
Subgroup analysis of live birth rate for different treatment characteristics
| Characteristics | >5% decrease | ±5% plateau | >5% increase |
|---|---|---|---|
| Embryo transfer number | |||
| Single | |||
| Live birth, n/N (%) | 16/51 (31.4) | 34/142 (23.9) | 47/157 (29.9) |
| Crude OR (95% CI) | 1.45 (0.72–2.94) | Reference | 1.36 (0.81–2.27) |
| Adjusted OR (95% CI) | 1.65 (0.74–3.68) | Reference | 1.59 (0.89–2.86) |
| Double | |||
| Live birth, n/N (%) | 145/354 (41.0) | 494/1,117 (44.2) | 421/947 (44.5) |
| Crude OR (95% CI) | 0.88 (0.69–1.12) | Reference | 1.01 (0.85–1.20) |
| Adjusted OR (95% CI) | 0.84 (0.65–1.08) | Reference | 1.01 (0.84–1.22) |
| Embryo developmental stage | |||
| Cleavage stage | |||
| Live birth, n/N (%) | 134/359 (37.3) | 477/1,146 (41.6) | 427/1,008 (42.4) |
| Crude OR (95% CI) | 0.84 (0.65–1.07) | Reference | 1.03 (0.87–1.22) |
| Adjusted OR (95% CI) | 0.81 (0.62–1.04) | Reference | 1.06 (0.88–1.27) |
| Blastocyst stage | |||
| Live birth, n/N (%) | 27/46 (58.7) | 51/113 (45.1) | 41/96 (42.7) |
| Crude OR (95% CI) | 1.73 (0.86–3.46) | Reference | 0.91 (0.52–1.57) |
| Adjusted OR (95% CI) | 1.70 (0.76–3.82) | Reference | 0.84 (0.44–1.61) |
| Endometrial thickness on trigger day | |||
| <8 mm | |||
| Live birth, n/N (%) | 4/16 (25.0) | 14/41 (34.1) | 24/80 (30.0) |
| Crude OR (95% CI) | 0.64 (0.18–2.37) | Reference | 0.83 (0.37–1.85) |
| Adjusted OR (95% CI) | 0.57 (0.12–2.63) | Reference | 0.57 (0.21–1.52) |
| ≥8 mm | |||
| Live birth, n/N (%) | 157/389 (40.4) | 514/1,218 (42.2) | 444/1,024 (43.4) |
| Crude OR (95% CI) | 0.93 (0.74–1.17) | Reference | 1.05 (0.89–1.24) |
| Adjusted OR (95% CI) | 0.88 (0.69–1.13) | Reference | 1.04 (0.87–1.24) |
| ≥14 mm | |||
| Live birth, n/N (%) | 20/42 (47.6) | 81/162 (50.0) | 9/22 (40.9) |
| Crude OR (95% CI) | 0.91 (0.46–1.79) | Reference | 0.69 (0.28–1.71) |
| Adjusted OR (95% CI) | 0.73 (0.33–1.58) | Reference | 0.87 (0.32–2.38) |
| Spontaneous LH surge | |||
| No | |||
| Live birth, n/N (%) | 62/150 (41.3) | 199/468 (42.5) | 210/488 (43.0) |
| Crude OR (95% CI) | 0.95 (0.66–1.38) | Reference | 1.02 (0.79–1.32) |
| Adjusted OR (95% CI) | 0.91 (0.61–1.36) | Reference | 1.07 (0.80–1.41) |
| Yes | |||
| Live birth, n/N (%) | 99/255 (38.8) | 329/791 (41.6) | 258/616 (41.9) |
| Crude OR (95% CI) | 0.89 (0.67–1.19) | Reference | 1.01 (0.82–1.25) |
| Adjusted OR (95% CI) | 0.85 (0.63–1.16) | Reference | 1.04 (0.83–1.31) |
OR, odds ratio; CI, confidence interval.